Intuitive Surgical, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- David J. Rosa
- Full Time Employees
- 17,021
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 1020 Kifer Road Sunnyvale CA United States of America 94086-5304
- IPO Date
- Jun 16, 2000
- CIK
- 0001035267
- Website
- intuitive.com
- Similar Companies
- Business
- Intuitive Surgical, Inc. develops, manufactures, and markets advanced robotic-assisted surgical systems designed to enhance the quality and access to minimally invasive care globally. Its core products include the da Vinci Surgical System, which enables surgeons to perform a wide range of complex surgical procedures across specialties such as general surgery, urology, gynecology, cardiothoracic, and head and neck surgery using minimally invasive techniques. The company also offers the Ion Endoluminal System, a robotic platform for diagnostic endoluminal procedures enabling minimally invasive lung biopsies through advanced imaging and navigation technology. Intuitive’s product suite includes stapling, energy, and core instrumentation compatible with its multi-port da Vinci systems, alongside progressive learning pathways that facilitate clinical adoption, and a comprehensive infrastructure of service and support including installation, maintenance, technical support, proactive system health monitoring, and integrated digital capabilities that provide hospitals with data-driven insights to optimize surgical performance. Founded in 1995 and headquartered in Sunnyvale, California, Intuitive Surgical operates globally, supporting hospitals and surgical teams across over 60 countries. In the last 1-2 years, the company has advanced the commercial launch of its da Vinci 5 Surgical System, receiving regulatory clearances from the US FDA and CE mark in 2024, with 2025 focused on scaling the adoption of this platform through enhanced hardware and software upgrades featuring increased computing power and digital capabilities. Intuitive reported significant growth in system placements and procedure volumes, with a 14% year-over-year increase in installed base and 17% procedural growth as of mid-2025. Strategic priorities include expanding its robotic surgery ecosystem, reinforcing its recurring revenue model—which accounted for 84% of revenue in 2024—and furthering its Quintuple Aim framework aimed at improving patient outcomes, care team experience, access to care, and lowering total costs. Additionally, leadership transitioned in mid-2025 with President Dave Rosa promoted to CEO, signaling a new phase of growth and innovation focus. Despite rising competition in the robotic surgery field, Intuitive remains a dominant market leader through continuous technological innovation and strategic expansion. This comprehensive offering positions Intuitive Surgical as a pioneer and global leader in robotic-assisted, minimally invasive surgical technology, serving healthcare providers with products, services, and digital innovations that collectively enhance surgical precision, patient recovery, and overall healthcare system efficiency.
Company News
3 Stocks Whose Competitive Walls Tower Over Nvidia's
Intuitive Surgical's Worst Stretch in Years Isn't Scaring Wall Street -- Here's What Analysts Are Focused On Instead
Why Is ISRG Investing More Aggressively in R&D Despite Macro Headwinds?
Intuitive Surgical, Inc. (ISRG) Gains As Market Dips: What You Should Know
Intuitive Surgical's Record Cash Flow Gives It an Innovation Advantage
ISRG vs. MDT: Which Surgical Robot Stock Is the Smarter Buy?
Wall Street Bulls Look Optimistic About Intuitive Surgical (ISRG): Should You Buy?
Intuitive Surgical Expands Manufacturing Footprint in Asia Pacific
Intuitive Surgical Stock Is Having Its Worst Year Since 2008. What's Behind the Sell-Off?
Thinking About Buying SpaceX? These 2 Stocks Should Be Better Bets
Is ISRG's Software Strategy Becoming as Important as Its Robots?
Breakfast News: Week in Review
Breakfast News: BBB Foods Opens Shops at Full Tilt
ISRG's US Procedure Growth Slows: Is ACA Headwind a Temporary Concern?
Intuitive Surgical: Priced For Precision
This Intuitive Surgical Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
Intuitive Surgical (ISRG) Stock Has Plunged 33% in 2026. Here's Why One Fund Manager Remains Bullish -- and Why I Do, Too.
Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Marriott International, Merck, Novo Nordisk, Okta, and More
Oppenheimer Sees $500 for Intuitive Surgical as Rivals Stall
The Number One Reason I Keep Buying Intuitive Surgical Now For The Long Run